close

Maxygen, Inc., a biotechnology company, engages in the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. It primarily uses its MolecularBreeding directed evolution technology platform, along with ancillary technologies, to create proprietary proteins. The company's product candidates include MAXY-G34, which completed a Phase IIa clinical trial, is designed to be an improved next-generation pegylated, G-CSF for the treatment of neutropenia associated with cancer chemotherapy treatments; and MAXY-4 products that are designed to be CTLA-4 Ig therapeutics for the treatment of an array of autoimmune disorders, including rheumatoid arthritis. Its earlier stage programs in preclinical research include a preventative HIV vaccine. Maxygen, Inc. has a collaboration agreement with Astellas Pharma, Inc. for the development and commercialization of MAXY-4 product candidates for autoimmune diseases and transplant rejection; and a joint venture agreement to focus on the discovery, research, and development of multiple protein pharmaceutical programs, including MAXY-4 program and other early stage programs. The company was founded in 1996 and is headquartered in Redwood City, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	5.90
Volume	388021
Volume Avg	118023
52 Week High	6.20
52 Week Low	4.07
PE	3.11
PE (group average)	39
EPS Year	1.80
EPS change Q/Q	-97.92%
EPS change Q/Q Yr ago	-1000%
EPS change Q/Q next Q est	-100%
EPS change Y/Y	1000%
REV change Q/Q	100%
REV change Q/Q Yr ago	100%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%